SCHEMBL4142247

SCHEMBL4142247

CC1(C)OB(c2ccc(-c3cn4cc(N)ccc4n3)cc2)OC1(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.50
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
PAX8 Q06710 2/20 0.46
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
MITF O75030 1/20 0.46
KDM5A P29375 1/20 0.46
KDM5C P41229 1/20 0.46
LPL P06858 6/20 0.43
LIPG Q9Y5X9 6/20 0.43
ALDH1A3 P47895 4/20 0.41
ALDH1A2 O94788 1/20 0.41
SLC2A1 P11166 1/20 0.41
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2735666 0.84 NPC1 (0.59) APPNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL23753416 0.82 APP (0.58) APPNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL220154 0.82 RAB9A (0.58) APPNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL1726545 0.81 RAB9A (0.56) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL2127350 0.79 APP (0.69) APPNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL20480347 0.76 PIK3CG (0.47) LPLLIPG
SCHEMBL2127137 0.73 ALDH1A3 (0.65) APPNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL12380447 0.73 NPC1 (0.61) APPNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4157927 0.73 NPC1 (0.69) APPNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4781380 0.73 RAB9A (0.75) APPNPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
EP-1971599-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SmithKline Beecham Corporation (US) 2008-09-24 EP disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 WO disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds EIF2AK2, HAVCR2, MAVS APP 4884/4885NPC1 1833/4885RAB9A 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.